Saturday, November 7, 2026 · Evening · Health

We Being News

Saturday, November 7, 2026 · Evening · Health 3 pages

Front page · Health

Obesity drugs gain dementia prevention attention
Effectiveness remains uncertain so far

Obesity treatments like Wegovy and Mounjaro are being studied to see if they help prevent dementia and cancer.

1 pagesObesity drugs gain dementia prevention attention Effectiveness remains uncertain so farHealth
2 pagesOrganoid Treatment Guidelines First Established Globally by MFDSHealth
3 pages14 Rare-Disease Drugs Applied Selection Fairness QuestionedHealth

Health · Under review · 2 sources combinedp. 1 / 3

Obesity drugs gain dementia prevention attention
Effectiveness remains uncertain so far

In short

Obesity treatments like Wegovy and Mounjaro are being studied to see if they help prevent dementia and cancer.

Animal tests and some observational studies showed promise, but clear effects have not been confirmed in actual clinical trials.

Experts say the mechanism of action and long-term safety need further investigation.

Key facts

When	The international journal Science published a special paper on November 5 (local time).
Who	A joint research team from University of Gothenburg in Sweden and University of Copenhagen in Denmark published a review article.
What	They comprehensively reviewed brain protection and dementia prevention potential of GLP-1 class obesity drugs.
How	Animal tests and some observational studies showed associations, but clinical trials have not proven the effect.

What it means for me

If you take or are considering obesity drugs, note that dementia prevention effects are not yet established.

Seniors should be cautious as rapid weight loss can reduce muscle mass and worsen physical function.

Health · 2 sources combinedp. 2 / 3

Organoid Treatment Guidelines
First Established Globally by MFDS

In short

The Ministry of Food and Drug Safety (MFDS) has created the world's first evaluation guidelines for organoid cell therapies.

A domestic company, Organoid Science, solely conducted the foundational research for these guidelines.

The guidelines were explained at an educational session held on the 6th in Gangnam-gu, Seoul.

Key facts

When	The guidelines were established and published on October 29th, and an implementation workshop was held on the 6th.
Who	Organoid Science independently carried out commissioned research for the MFDS.
What	Quality and non-clinical evaluation guidelines for organoid-based cell therapies were created.
How	Evaluation considerations were provided, including 3D structure, cellular composition, in-vivo distribution, and tumorigenicity.

What it means for me

There will be no direct change to daily life, but this news could influence the speed of domestic biopharmaceutical new drug development.

Health · Planned · 4 sources combinedp. 3 / 3

14 Rare-Disease Drugs Applied
Selection Fairness Questioned

In short

A pilot program is underway to speed up coverage of rare-disease treatments under national health insurance.

Thirteen pharmaceutical companies applied for about 14 drugs, and the government reviewed them on the 4th.

Patient groups demanded fairness in the selection process and priority for patient treatment.

Key facts

When	Patient groups released their position on November 2nd, and the government held a selection review committee meeting on the 4th.
Who	The Korea Patient Groups Association and the Korea Rare and Intractable Disease Association each issued statements.
What	The issue concerns selection of 14 rare-disease treatment drugs applied for by 13 pharmaceutical companies for expedited coverage.
How	The patient groups association refused to participate in the review citing fairness concerns, while the rare disease association demanded broader selection.

What it means for me

Rare-disease patients and their families are directly affected by whether treatment drugs are covered by national health insurance.

You've read it all

The morning edition comes out tomorrow at 6:30 a.m.

Back to the front page

Get the app and we'll let you know when a new paper is out

Obesity drugs gain dementia prevention attentionEffectiveness remains uncertain so far

Obesity drugs gain dementia prevention attentionEffectiveness remains uncertain so far

In short

Key facts

What it means for me

Organoid Treatment GuidelinesFirst Established Globally by MFDS

In short

Key facts

What it means for me

14 Rare-Disease Drugs AppliedSelection Fairness Questioned

In short

Key facts

What it means for me

You've read it all

Obesity drugs gain dementia prevention attention
Effectiveness remains uncertain so far

Obesity drugs gain dementia prevention attention
Effectiveness remains uncertain so far

Organoid Treatment Guidelines
First Established Globally by MFDS

14 Rare-Disease Drugs Applied
Selection Fairness Questioned